Announcement on Receiving Approval for Clinical Trial of Class 1 Innovative Drug NH130 Tablets

Jiangsu Nhwa Pharmaceutical Co., Ltd.·August 18, 2026·2 pages

✨ AI Summary

Jiangsu Enhua Pharmaceutical Co., Ltd. announced it received approval from the NMPA for the clinical trial of its Class 1 innovative drug, NH130 citrate tablets. The drug is intended for treating schizophrenia and Alzheimer's disease with psychotic disorder. The company expects to conduct clinical trials and will apply for production approval upon successful completion.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 002262

Stock Abbreviation: Enhua Pharmaceutical

Announcement No.: 2026-033

Jiangsu Enhua Pharmaceutical Co., Ltd.

Announcement on Receiving Approval for Clinical Trial of Class 1 Innovative Drug NH130 Tablets

The Company and all members of the Board of Directors guarantee that the information disclosed in this announcement is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions for which they shall bear joint and several liability.

Jiangsu Enhua Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently received the "Drug Clinical Trial Approval Notification" for Class 1 chemical drug NH130 citrate tablets, issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"), and will commence clinical trials in the near future. The relevant situation is hereby announced as follows:

I. Basic Information of the Drug

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.